Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight.
Niemann-Pick disease, type C1 (NPC1) is a fatal, neurodegenerative disorder for which there is no definitive therapy. In NPC1, a pathological cascade including neuroinflammation, oxidative stress and neuronal apoptosis likely contribute to the clinical phenotype. While the genetic cause of NPC1 is k...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3483225?pdf=render |
id |
doaj-498e3e88435247388beea6df7c439897 |
---|---|
record_format |
Article |
spelling |
doaj-498e3e88435247388beea6df7c4398972020-11-25T01:02:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01710e4784510.1371/journal.pone.0047845Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight.Stephanie M ColognaXiao-Sheng JiangPeter S BacklundCeline V M CluzeauMichelle K DailNicole M YanjaninStephan SiebelCynthia L TothHyun-sik JunChristopher A WassifAlfred L YergeyForbes D PorterNiemann-Pick disease, type C1 (NPC1) is a fatal, neurodegenerative disorder for which there is no definitive therapy. In NPC1, a pathological cascade including neuroinflammation, oxidative stress and neuronal apoptosis likely contribute to the clinical phenotype. While the genetic cause of NPC1 is known, we sought to gain a further understanding into the pathophysiology by identifying differentially expressed proteins in Npc1 mutant mouse cerebella. Using two-dimensional gel electrophoresis and mass spectrometry, 77 differentially expressed proteins were identified in Npc1 mutant mice cerebella compared to controls. These include proteins involved in glucose metabolism, detoxification/oxidative stress and Alzheimer disease-related proteins. Furthermore, members of the fatty acid binding protein family, including FABP3, FABP5 and FABP7, were found to have altered expression in the Npc1 mutant cerebellum relative to control. Translating our findings from the murine model to patients, we confirm altered expression of glutathione s-transferase α, superoxide dismutase, and FABP3 in cerebrospinal fluid of NPC1 patients relative to pediatric controls. A subset of NPC1 patients on miglustat, a glycosphingolipid synthesis inhibitor, showed significantly decreased levels of FABP3 compared to patients not on miglustat therapy. This study provides an initial report of dysregulated proteins in NPC1 which will assist with further investigation of NPC1 pathology and facilitate implementation of therapeutic trials.http://europepmc.org/articles/PMC3483225?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephanie M Cologna Xiao-Sheng Jiang Peter S Backlund Celine V M Cluzeau Michelle K Dail Nicole M Yanjanin Stephan Siebel Cynthia L Toth Hyun-sik Jun Christopher A Wassif Alfred L Yergey Forbes D Porter |
spellingShingle |
Stephanie M Cologna Xiao-Sheng Jiang Peter S Backlund Celine V M Cluzeau Michelle K Dail Nicole M Yanjanin Stephan Siebel Cynthia L Toth Hyun-sik Jun Christopher A Wassif Alfred L Yergey Forbes D Porter Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. PLoS ONE |
author_facet |
Stephanie M Cologna Xiao-Sheng Jiang Peter S Backlund Celine V M Cluzeau Michelle K Dail Nicole M Yanjanin Stephan Siebel Cynthia L Toth Hyun-sik Jun Christopher A Wassif Alfred L Yergey Forbes D Porter |
author_sort |
Stephanie M Cologna |
title |
Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. |
title_short |
Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. |
title_full |
Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. |
title_fullStr |
Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. |
title_full_unstemmed |
Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. |
title_sort |
quantitative proteomic analysis of niemann-pick disease, type c1 cerebellum identifies protein biomarkers and provides pathological insight. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Niemann-Pick disease, type C1 (NPC1) is a fatal, neurodegenerative disorder for which there is no definitive therapy. In NPC1, a pathological cascade including neuroinflammation, oxidative stress and neuronal apoptosis likely contribute to the clinical phenotype. While the genetic cause of NPC1 is known, we sought to gain a further understanding into the pathophysiology by identifying differentially expressed proteins in Npc1 mutant mouse cerebella. Using two-dimensional gel electrophoresis and mass spectrometry, 77 differentially expressed proteins were identified in Npc1 mutant mice cerebella compared to controls. These include proteins involved in glucose metabolism, detoxification/oxidative stress and Alzheimer disease-related proteins. Furthermore, members of the fatty acid binding protein family, including FABP3, FABP5 and FABP7, were found to have altered expression in the Npc1 mutant cerebellum relative to control. Translating our findings from the murine model to patients, we confirm altered expression of glutathione s-transferase α, superoxide dismutase, and FABP3 in cerebrospinal fluid of NPC1 patients relative to pediatric controls. A subset of NPC1 patients on miglustat, a glycosphingolipid synthesis inhibitor, showed significantly decreased levels of FABP3 compared to patients not on miglustat therapy. This study provides an initial report of dysregulated proteins in NPC1 which will assist with further investigation of NPC1 pathology and facilitate implementation of therapeutic trials. |
url |
http://europepmc.org/articles/PMC3483225?pdf=render |
work_keys_str_mv |
AT stephaniemcologna quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT xiaoshengjiang quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT petersbacklund quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT celinevmcluzeau quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT michellekdail quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT nicolemyanjanin quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT stephansiebel quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT cynthialtoth quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT hyunsikjun quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT christopherawassif quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT alfredlyergey quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight AT forbesdporter quantitativeproteomicanalysisofniemannpickdiseasetypec1cerebellumidentifiesproteinbiomarkersandprovidespathologicalinsight |
_version_ |
1725203922999574528 |